Mekinist 2mg Tablets (Trametinib) – Original Anti-Cancer Medicine in Pakistan
Mekinist® contains trametinib 2 mg, a targeted anticancer medicine known as a MEK inhibitor. It is used to treat certain cancers that have specific genetic changes, particularly BRAF V600 mutations, confirmed by an approved diagnostic test.
Mekinist may be prescribed alone or in combination with dabrafenib, depending on the cancer type and your oncologist's treatment plan. It works by blocking abnormal signaling pathways that promote the growth and spread of cancer cells.
Benefits
- Targeted treatment for cancers with eligible BRAF mutations.
- Helps slow or stop the growth of cancer cells.
- May reduce tumor progression in appropriate patients.
- Often used in combination with dabrafenib for improved treatment outcomes in approved indications.
- Oral tablet taken once daily.
- Personalized therapy based on tumor genetic testing.
- Used according to internationally recognized oncology treatment guidelines.
Features
- Contains Trametinib 2 mg.
- Prescription-only targeted cancer therapy.
- Oral tablet formulation.
- Once-daily dosing.
- May be used alone or with dabrafenib as directed by an oncologist.
- Intended for cancers with confirmed eligible BRAF mutations.
- Manufactured under strict pharmaceutical quality standards.
How It Works
Trametinib inhibits MEK1 and MEK2 proteins, which are part of the MAPK signaling pathway involved in cell growth. In cancers with certain BRAF mutations, this pathway is overactive. By blocking MEK activity, Mekinist helps reduce cancer cell growth and proliferation. In many approved uses, combining trametinib with dabrafenib provides more effective pathway inhibition than either medicine alone.
Who Can Use
Mekinist may be prescribed for adults with appropriate clinical indications, including:
- BRAF V600 mutation-positive unresectable or metastatic melanoma.
- Certain cases of resected melanoma as adjuvant therapy (with dabrafenib).
- Selected patients with BRAF V600E-positive non-small cell lung cancer (NSCLC).
- Certain BRAF V600E-positive anaplastic thyroid cancers (with dabrafenib).
- Other approved solid tumors with eligible BRAF mutations, as determined by current prescribing information and clinical guidelines.
Not suitable without specialist advice for:
- Pregnant women.
- Breastfeeding women.
- Patients with known allergy to trametinib or any ingredient.
- Individuals with severe uncontrolled medical conditions unless assessed by an oncologist.
- Children unless specifically prescribed by a pediatric oncology specialist where approved.
How to Use
- Use only as prescribed by your oncologist.
- Take one tablet once daily or exactly as directed.
- Take on an empty stomach (at least 1 hour before or 2 hours after food).
- Swallow the tablet whole with water.
- Take it at the same time every day.
- Do not change the dose or stop treatment without your doctor's advice.
- If you miss a dose, follow your healthcare provider's instructions or the official prescribing information.
Doctor Permission
Mekinist requires a specialist oncologist's prescription.
Before starting treatment, your doctor may evaluate:
- Confirmation of a qualifying BRAF mutation.
- Heart function (including ejection fraction).
- Eye health and vision.
- Liver and kidney function.
- Lung symptoms or interstitial lung disease risk.
- Blood pressure and general health.
- Pregnancy status in women of childbearing potential.
- Other medicines to assess potential interactions.
Seek immediate medical attention if you develop severe fever, chest pain, breathing difficulty, vision changes, significant bleeding, or symptoms of heart problems.
Frequently Asked Questions (FAQs)
1. What is Mekinist used for?
Mekinist is a targeted anticancer medicine used to treat certain cancers with specific BRAF gene mutations, including melanoma and some other approved cancers.
2. What is the active ingredient?
Each tablet contains Trametinib 2 mg.
3. Is Mekinist chemotherapy?
No. Mekinist is a targeted therapy (MEK inhibitor), not traditional chemotherapy.
4. Can Mekinist be taken alone?
Yes, for some indications. For many approved uses, it is prescribed together with dabrafenib, depending on the cancer type and treatment guidelines.
5. How should Mekinist be taken?
It is usually taken once daily on an empty stomach, exactly as directed by your oncologist.
6. What are the common side effects?
Common side effects may include:
- Rash
- Diarrhea
- Fatigue
- Swelling (edema)
- Fever (especially when combined with dabrafenib)
- Nausea
- High blood pressure
Your healthcare team will monitor you for side effects throughout treatment.
7. Can pregnant women use Mekinist?
No. Mekinist may harm an unborn baby. Effective contraception should be used during treatment and for the period recommended by your healthcare provider after stopping therapy.
8. Is a prescription required?
Yes. Mekinist is a prescription-only medicine and should only be used under the care of an oncology specialist.
9. How should Mekinist be stored?
Store according to the manufacturer's instructions, typically under refrigeration as specified in the product labeling, and keep it in the original packaging away from children.
10. Is Mekinist available in Pakistan?
Yes. Mekinist may be available through specialized oncology pharmacies, hospital pharmacies, and authorized importers in Pakistan. Availability can vary, and a valid prescription from an oncologist is generally required.
Customers Reviews For Mekinist 2Mg Tablets In Pakistan